Skip to main navigation

Find a Doctor »

x

Neuronetics
For Patients
For Physicians

For Patients
For Physicians
Neuronetics

Why NeuroStar
About NeuroStar
Patient Corner
Insurance

About NeuroStar
Technology
Practice Support
Insurance

Solutions
Investors
Meet the Team
News
Careers

Contact Us
Global Sites
- English
- Deutsch
- 日本語
- 한국어

How it Works
Safety & Tolerability
Is it Right for You?
Clinical Results

Proven Efficacy
Safety
Mechanism of Action
The Key Role
Qualified Candidates
Scientific Publications

Unique Coil
TrakStar
MT Assist
Contact Sensing Advantage
Practice Setting
Physician Experiences

Success Program
Clinical Training
Field Service
Patient Education
Public Relations
Providers
Events and Exhibits

Coding and Billing
Medical Coverage Policies
Health Insurance Coverage
Services
Resources

Overview
Stock Information
News & Events
Financial Information
Corporate Governance
Investor Resources

Neuronetics Board

Precision
Facts vs Myths
About Depression

News Releases

News Releases

Events and Presentations

Press Coverage
News Releases
Investor Calendar
Presentations

Keyword Search

Year

02/23/21

NeuroStar® Advanced Therapy Outcomes Registry Clinical Data Published in Brain Stimulation Validates Depression Treatment Protocols

02/16/21

Neuronetics to Report Fourth Quarter and Fiscal Year 2020 Financial and Operating Results and Host Conference Call

02/11/21

Neuronetics Announces Strategic Leadership Promotions to Support Future Growth

02/10/21

Neuronetics to Participate at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

02/02/21

Neuronetics Announces Closing of Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

01/28/21

Neuronetics Announces Pricing of $75 Million Public Offering of Common Stock

01/28/21

Neuronetics Announces Proposed Public Offering of Common Stock

01/19/21

NeuroStar® Advanced Therapy’s Depression Outcomes Registry Hits 10,000 Patient Milestone

01/12/21

Neuronetics Reports Preliminary Fourth Quarter and Fiscal Year 2020 Financial Results

01/07/21

Neuronetics to Participate at the 23rd Annual ICR Westwicke Conference

01/07/21

Neuronetics Announces Expansion of Sales Organization

Printer Friendly Version

View printer-friendly version

RSS Feeds

E-mail Alerts

E-mail Alerts

View contacts

View contacts

Indication

NeuroStar TMS Therapy is indicated for the treatment of Major Depressive Disorder in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode.

NeuroStar TMS Therapy is only available by prescription. A doctor can help decide if NeuroStar TMS Therapy is right for you.

Important Safety Information

The most common side effect is pain or discomfort at or near the treatment site. These events are transient; they occur during the TMS treatment course and do not occur for most patients after the first week of treatment. There is a rare risk of seizure associated with the use of NeuroStar TMS (<0.1% per patient).

NeuroStar TMS Therapy should not be used with patients who have non-removable conductive metal in or near the head. NeuroStar TMS Therapy has not been studied in patients who have not received prior antidepressant treatment.
Safety and Prescribing Information »

Our Commitment

Neuronetics is committed to compliance with state and federal laws regarding interaction with healthcare providers.
Commitment to Compliance »

Neuronetics Resources
- Solutions
- Investors
- Team
- Careers
- Find a Doctor
About NeuroStar
International
- English
- Deutsch
- 日本語
- 한국어
Website
Contact Us
- 1-877-600-7555
- Facebook
- Twitter
- Instagram
- YouTube
- LinkedIn

Copyright @ 2021 Neuronetics. All Rights Reserved.